Kalaris reports positive expanded Phase 1a data for TH103 in nAMD; 29% no retreatment in 6 months

Kalaris Therapeutics, Inc.

Expanded Phase 1a SAD dataset: 17 treatment-naïve + 3 treatment-experienced patients; all 20 completed 6-month follow-up.
After single TH103 injection, 41% of treatment-naïve patients retreatment at ≥4 months, 29% no anti-VEGF treatment in 6 months.
Mean 9.2-letter BCVA improvement, 118µm CST reduction, 93% reduction in intraretinal fluid at one month.
TH103 plasma Cmax 27- to 53-fold lower vs leading anti-VEGF agents on molar equivalence basis.
No IOI at 2.5 mg with improved manufacturing; Phase 1b/2 enrolling, initial data expected 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.